Company: BFRG
Filing Date: 2025-03-14
Form Type: 10-K
Source: 0001493152-25-010367
Chunk: 941

Company: BullFrog AI Holdings, Inc.
Filing Date: 2025-03-14
Form: 10-K
Item: Item 9
Chunk 941
---
. 

Other
than as disclosed in this Note 12 and as may be disclosed elsewhere in the notes to the accompanying consolidated financial statements,
there have been no subsequent events that require adjustment or disclosure in the accompanying consolidated financial statements.

In
February 2025, the Company announced its entry into a collaboration agreement with Eleison Pharmaceuticals Inc. (“Eleison”),
a Phase III oncology company focused on novel chemotherapeutic treatments for rare cancers. Through this collaboration, the Company will
apply its proprietary Bullfrog Data Networks™ solution, powered by the bfLEAP® platform, to analyze clinical data from Eleison’s
ongoing Phase III trial and previous clinical studies of glufosfamide, an investigational treatment for pancreatic cancer. The platform
will evaluate the current trajectory of the trial with respect to safety signals, extract predictive biomarkers for efficacy and safety
performance from prior studies to support future trial design, and provide data-driven insights to optimize Eleison’s planned clinical
trials for inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). These insights are expected to streamline trial efficiency
and improve decision-making for Eleison’s broader oncology pipeline.

In
March 2025, the Company anticipates making a severance payment to a former employee for approximately $45,000.

 F-18